Abstract:Two series of new pyridyl-bearing fused bicyclic analogues designed to target the dual-tolerant regions of the non-nucleoside reverse transcriptase inhibitor (NNRTI)-binding pocket were synthesized and evaluated for their anti-HIV activities. Several compounds, such as 6, 14, 15, 21, 30, and 33, were found to be potent inhibitors against the wild-type (WT) HIV-1 strain or multiple NNRTI-resistant strains at low nanomolar levels. Detailed structure–activity relationships were obtained by utilizing the variation of moieties within the corresponding pharmacophores. In vitro metabolic stability profiles and some drug-like properties of selected compounds were assessed, furnishing the preliminary structure–metabolic stability relationships. Furthermore, molecular modeling studies elucidated the binding modes of compounds 6, 15, 21, and 30 in the binding pocket of WT, E138K, K103N, or Y181C HIV-1 RTs. These promising compounds can be used as lead compounds and warrant further structural optimization to yield more active HIV-1 inhibitors.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00987.Molecular formula strings (CSV)In vitro anti-HIV assays in MT-4 cells; WT HIV-1 RT inhibition assays; metabolic stability assays in human liver microsomes; molecular modeling; predicted miLogP and MolLogP values of target compounds and controls; mean distance and standard deviation values for selected ligand–protein contacts in simulated systems; regression analysis of miLogP values and MolLogP values; rmsd profiles for the protein backbone, NNRTI-binding site, and simulated inhibitors for the RT-inhibitor complexes; time-dependent distance distribution for d1–d4 for RT-inhibitor complexes; representation of the molecular interaction potential for the interaction of compounds 6, 15, 21, and 30 with a positively and a negatively charged atom; and 1H NMR, 13C NMR, and ESI-MS spectra for the target compounds (PDF).This article has not yet been cited by other publications.

Improving the Positional Adaptability: Structure-Based Design of Biphenyl-Substituted Diaryltriazines As Novel Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors

Structure-based Design of Novel Heterocycle-Substituted ATDP Analogs As Non-Nucleoside Reverse Transcriptase Inhibitors with Improved Selectivity and Solubility

Structure-guided Design of Novel Biphenyl-Quinazoline Derivatives As Potent Non-Nucleoside Reverse Transcriptase Inhibitors Featuring Improved Anti-Resistance, Selectivity, and Solubility

Structure-based design of diarylpyrimidines and triarylpyrimidines as potent HIV-1 NNRTIs with improved metabolic stability and drug resistance profiles

Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors.

Discovery of Novel Amino Acids (Analogues)-Substituted Thiophene[3,2- d]pyrimidine Derivatives as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: Design, Synthesis, and Biological Evaluation

Structure-directed expansion of biphenyl-pyridone derivatives as potent non-nucleoside reverse transcriptase inhibitors with significantly improved potency and safety

Design of Biphenyl-Substituted Diarylpyrimidines with a Cyanomethyl Linker as HIV-1 NNRTIs via a Molecular Hybridization Strategy.

Structure-based linker optimization of 6-(2-cyclohexyl-1-alkyl)-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors

Follow On-Based Optimization of the Biphenyl-Dapys As HIV-1 Nonnucleoside Reverse Transcriptase Inhibitors Against the Wild-Type and Mutant Strains.

[Design, Synthesis and Biologic Evaluation of Diarylbenzimidazole Derivatives As Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors].

Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies

Design of the naphthyl-diarylpyrimidines as potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) via structure-based extension into the entrance channel.

Synthesis and biological activity of naphthyl-substituted (B-ring) benzophenone derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.

Design, Synthesis, and Evaluation of Diarylpyridines and Diarylanilines As Potent Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.

Towards New C6-rigid S-DABO HIV-1 Reverse Transcriptase Inhibitors: Synthesis, Biological Investigation and Molecular Modeling Studies

Structure-based design and optimization lead to the identification of novel dihydrothiopyrano[3,2- d]pyrimidine derivatives as potent HIV-1 inhibitors against drug-resistant variants

Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: from Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs

Design and Synthesis of a New Series of Cyclopropylamino-Linking Diarylpyrimidines As HIV Non-Nucleoside Reverse Transcriptase Inhibitors.

Discovery of novel diarypyrimidine derivatives bearing six-membered non-aromatic heterocycles as potent HIV-1 NNRTIs with improved anti-resistance and drug-like profiles

Design, Synthesis, and Biological Evaluation of Novel 4‐aminopiperidinyl‐linked 3,5‐disubstituted‐1,2,6‐thiadiazine‐1,1‐dione Derivatives As HIV‐1 NNRTIs